EUTECNIQ Sciences

See every page on one mapArrow keys move through results · Enter opens · Esc closes

Insights · New frontiers Peer-reviewed papers Registry and agency records EUTECNIQ proposed

New frontiers

Between 2013 and 2026, three things changed in natural-product science: long plant pathways were rebuilt in yeast and in tobacco leaves, genome mining and molecular networking turned sequence and spectra into searchable chemistry, and a handful of plant- and fungus-derived compounds reached late-phase registered trials. Each entry below is tied to the paper or record that reports it.

25 g/Lartemisinic acid from engineered yeast, the precursor of semi-synthetic artemisinin (2013)
17 genesexpressed in Nicotiana benthamiana to make baccatin III, the industrial paclitaxel precursor (2025)
101biosynthetic gene cluster types detectable by antiSMASH 8, up from 81 in version 7
3,059curated biosynthetic gene clusters in MIBiG 4.0

Status. This page reports other groups' published work and public registry records, read on October 28, 2026. EUTECNIQ has no laboratory, no strains, no data and no trials; the closing paragraph is a proposal.

Overview

What changed since 2013

Two lines of work carried most of the change. Pathways that plants run over many enzymatic steps were refactored into microbial and plant hosts, and the tools that assign structures to genes and to spectra were released openly and kept growing.

Twelve published advances, with the quantity each paper reportsPrimary papers
Timeline of published advances in natural-product science from 2013 to 2025: pathways rebuilt in microbial and plant hosts, open analytical resources and genome-mining releases, each labeled with the reported quantity and the journal.Published advances, 2013–2025 (year of publication)20132014201520162017201820192020202120222023202420252026Artemisinic acid inyeast: 25 g/L titerDeep eutectic mixtures:over 100 reportedGNPS: open MS/MSknowledge baseCannabinoids in yeast:from galactoseSIRIUS 4: structuresfrom MS/MSCANOPUS: 2,497compound classesVindoline in yeast: 30enzymatic stepsantiSMASH 7: 81 clustertypesQS-21 in yeast: 38heterologous enzymesMIBiG 4.0: 3,059curated clustersBaccatin III in plants:17-gene routeantiSMASH 8: 101cluster typesPublished advances in natural-product science from 2013 to 2025, listed by year with the reported quantity and the journal.Published advances, 2013–20252013Artemisinic acid in yeast25 g/L titer2013Deep eutectic mixturesover 100 reported2016GNPSopen MS/MS knowledge base2019Cannabinoids in yeastfrom galactose2019SIRIUS 4structures from MS/MS2021CANOPUS2,497 compound classes2022Vindoline in yeast30 enzymatic steps2023antiSMASH 781 cluster types2024MIBiG 4.03,059 curated clusters2024QS-21 in yeast38 heterologous enzymes2025Baccatin III in plants17-gene route2025antiSMASH 8101 cluster types
Each item is the paper listed in the table below; the year is the year of publication.
Published advances in natural-product science, 2013 to 2025, with the primary paper for each
YearAdvanceWhat the paper reportsPrimary paper (DOI)
2013Artemisinic acid in yeastFermentation titer of 25 g/L artemisinic acid in engineered S. cerevisiae, plus a chemical route to artemisinin using a chemical source of singlet oxygenPaddon et al., Nature 496:528–532. 10.1038/nature12051
2013Natural deep eutectic mixturesMore than 100 natural deep eutectic mixtures formed from plant primary metabolitesDai et al., Anal Chim Acta 766:61–68. 10.1016/j.aca.2012.12.019
2016GNPSOpen-access knowledge base for raw, processed and identified MS/MS data, with community reference libraries and continuous reanalysis of deposited dataWang et al., Nat Biotechnol 34:828–837. 10.1038/nbt.3597
2019Cannabinoids in yeastComplete biosynthesis of five cannabinoid acids in S. cerevisiae from galactose, and analogues from fed fatty acidsLuo et al., Nature 567:123–126. 10.1038/s41586-019-0978-9
2019SIRIUS 4Molecular formula and structure identification from tandem mass spectra, with identification rates above 70% on the reported metabolomics datasetsDührkop et al., Nat Methods 16:299–302. 10.1038/s41592-019-0344-8
2021CANOPUSCompound-class prediction for 2,497 classes from fragmentation spectra, with an average cross-validation accuracy of 99.7% on reference dataDührkop et al., Nat Biotechnol 39:462–471. 10.1038/s41587-020-0740-8
2022Vindoline and catharanthine in yeastDe novo production of both vinblastine precursors: 30 enzymatic steps beyond native metabolites, 56 genetic edits, 34 heterologous genesZhang et al., Nature 609:341–347. 10.1038/s41586-022-05157-3
2023antiSMASH 7Detectable cluster types raised from 71 to 81, with added chemical-structure prediction and cluster-regulation analysisBlin et al., Nucleic Acids Res 51:W46–W50. 10.1093/nar/gkad344
2024QS-21 in yeastComplete biosynthesis of the saponin adjuvant QS-21 and derivatives, requiring balanced expression of 38 heterologous enzymes from six organisms across seven enzyme familiesLiu et al., Nature 629:937–944. 10.1038/s41586-024-07345-9
2024MIBiG 4.03,059 curated gene-cluster entries after 557 new and 590 modified entries, from 8,304 edits by 267 contributorsZdouc et al., Nucleic Acids Res 53:D678–D690 (published December 2024, 2025 issue). 10.1093/nar/gkae1115
2025Baccatin III in a plant hostSeven newly resolved genes allow a 17-gene de novo route to baccatin III in N. benthamiana leaves, at levels the authors call comparable with natural abundance in Taxus needlesMcClune et al., Nature 643:582–592. 10.1038/s41586-025-09090-z
2025antiSMASH 8Detectable cluster types raised from 81 to 101, with improved terpenoid and tailoring-enzyme analysisBlin et al., Nucleic Acids Res 53:W32–W38. 10.1093/nar/gkaf334

Titles, journals, volumes and reported quantities read from each article record and abstract, October 28, 2026.

Biosynthesis

Pathways rebuilt in hosts

A pathway moves into a host when every enzyme in it is known, expressed and balanced. The published cases differ in how much of the molecule the host makes: some end at a precursor that chemistry finishes, and the reported scale ranges from fermenter titers to leaf-level isolation.

Published pathway reconstructions: target, host, reported pathway size and what the host produced
TargetHostPathway size, as reportedWhat the host producedSource
ArtemisininS. cerevisiaeComplete pathway to artemisinic acid, including a plant dehydrogenase and a second cytochrome described in the paperArtemisinic acid at 25 g/L; artemisinin made from it chemicallyPaddon 2013
Cannabinoid acidsS. cerevisiaeNative mevalonate pathway engineered, plus a multi-organism hexanoyl-CoA route and Cannabis genesFive cannabinoid acids from galactose, plus analogues from fed fatty acidsLuo 2019
Vinblastine precursorsS. cerevisiae30 enzymatic steps beyond native metabolites; 56 genetic edits; 34 heterologous genes; 10 yeast genes alteredVindoline and catharanthine; vinblastine by chemical coupling in vitroZhang 2022
QS-21S. cerevisiae38 heterologous enzymes from six organisms, across seven enzyme families, with plant compartmentalization mimicked in yeastQS-21, its precursors and structural analoguesLiu 2024
Baccatin IIIN. benthamiana17 genes, of which seven were newly resolved, plus the NTF2-like protein FoTO1 and a β-phenylalanine-CoA ligaseBaccatin III isolated from leaves; also 3′-N-debenzoyl-2′-deoxypaclitaxelMcClune 2025

Entries restate each paper's own abstract; DOIs in the table above. A reported titer is a laboratory or pilot result, not a cost of goods.

Long pathways are now reachable, but each case still ends in chemistry, purification and a supply decision.

Notes and sources

QS-21 is relevant beyond the laboratory: the adjuvant AS01B in the licensed recombinant zoster vaccine is composed of monophosphoryl lipid A and QS-21, "a saponin purified from Quillaja saponaria Molina plant extract", at 50 mcg per 0.5 mL dose (FDA-approved prescribing information, revised February 2026; initial U.S. approval 2017). The 2024 paper states that QS-21 "remains the only saponin-based adjuvant that has been clinically approved for use in humans" and that supply depends on extraction from the tree or low-yielding total synthesis. Nothing on this page claims that any yeast-made material has been used in a licensed product.

Plant cell fermentation

Cells instead of bark

The precedent for making a plant drug without the plant is older than the yeast work. Plant cell fermentation grows a selected Taxus cell line in aqueous medium in fermentation tanks, and the award record states what it removed from the previous semisynthetic route.

Paclitaxel sourcing routes and the figures published in the 2004 Presidential Green Chemistry Challenge award record
ItemFigure as published
Paclitaxel in Pacific yew barkAbout 0.0004% by weight
10-DAB in European yew leaves and twigsAbout 0.1% by dry weight; carries 8 of the chiral centers
Semisynthesis from 10-DAB11 chemical transformations, 7 isolations, 13 solvents and 13 organic reagents and other materials
Published total synthesesAbout 40 steps, overall yield about 2%
Plant cell fermentation routeNo chemical transformations, so six intermediates eliminated; ten solvents and six drying steps eliminated
Projected materials avoided, first five yearsAbout 71,000 pounds of hazardous chemicals and other materials

U.S. EPA, Presidential Green Chemistry Challenge: 2004 Greener Synthetic Pathways Award (Bristol-Myers Squibb Company), agency page read October 28, 2026. Figures are the award record's, including its projections.

Genome mining

Clusters you can search

Bacterial and fungal specialized metabolites are usually encoded by clustered genes, so a genome can be screened for chemistry before anything is grown. Two releases set the pace: a detector that covers more cluster types with each version, and a curated repository that records what a cluster makes.

antiSMASH detects more cluster types with each release: 71, then 81, then 101Release papers
Bar chart of the number of biosynthetic gene cluster types antiSMASH can detect: 71 before version 7, 81 in version 7 and 101 in version 8.Detectable biosynthetic gene cluster types, by antiSMASH release020406080100Cluster types (count)Before version 7, Cluster types detectable: 7171Before version 7antiSMASH 7 (2023), Cluster types detectable: 8181antiSMASH 7 (2023)antiSMASH 8 (2025), Cluster types detectable: 101101antiSMASH 8 (2025)Counts as stated in each release paper; version 7 reports the rise from 71 to 81, version 8 from 81 to 101.Number of biosynthetic gene cluster types antiSMASH can detect: 71 before version 7, 81 in version 7, 101 in version 8.Detectable cluster types, by releaseBefore version 7Before version 7: 71 cluster types71antiSMASH 7 (2023)antiSMASH 7 (2023): 81 cluster types81antiSMASH 8 (2025)antiSMASH 8 (2025): 101 cluster types101Counts as stated in the version 7 and version 8 releasepapers.
antiSMASH 7 (Nucleic Acids Res 2023;51:W46–W50) states the increase from 71 to 81 cluster types; antiSMASH 8 (Nucleic Acids Res 2025;53:W32–W38) states the increase from 81 to 101.
Open genome-mining resources with the counts stated in their release papers
ResourceReleaseCounts as statedWhat it does
antiSMASHVersion 7 (2023)81 cluster typesDetects and annotates biosynthetic gene clusters in bacterial, archaeal and fungal genomes; web server and open-source tool
antiSMASHVersion 8 (2025)101 cluster typesAdds terpenoid and tailoring-enzyme analysis and further work on modular polyketide synthases and nonribosomal peptide synthetases
MIBiGVersion 4.0 (published December 2024)3,059 curated entries; 557 new, 590 modified; 8,304 edits; 267 contributorsStandardized, machine-readable records of characterized clusters and their products, with a peer-review model for submissions

antiSMASH 7 and 8, and MIBiG 4.0 release papers (DOIs in the overview table). MIBiG began in 2015.

Cluster detection is strongest for bacteria and fungi; plant pathways are generally not clustered, which is why the plant cases above needed transcriptional work to find their genes.

Metabolomics

Spectra into structures

Untargeted mass spectrometry finds thousands of features in an extract, and most of them match nothing in a library. Three open tools narrowed that gap: a shared spectral knowledge base with molecular networking, a formula-and-structure engine, and a classifier that assigns a compound class when no structure can be named.

Open metabolomics tools, what each produces and the performance each paper reports
ToolOutputReported performancePaper
GNPSShared MS/MS libraries; molecular networking that groups spectra by similarity; continuous reanalysis of deposited dataNo single figure; the paper describes the infrastructure and community curationWang 2016
SIRIUS 4Molecular formula, then structure search against databases through CSI:FingerIDIdentification rates above 70% on the datasets reportedDührkop 2019
CANOPUSCompound class for a spectrum, including classes with no tandem-MS training data2,497 classes; average cross-validation accuracy 99.7% on reference dataDührkop 2021

Reported values are those stated in each paper's abstract; cross-validation accuracy is not the same as accuracy on new samples.

Related: how targeted and untargeted analysis differ, with a worked molecular network · analytical methods

Machine learning

What the reviews claim

Peer-reviewed reviews, not vendor material, are the defensible source here. Two of them set out the same conclusion: the computational methods are available, and the binding constraint is data quality and validation rather than algorithms.

Peer-reviewed reviews of computational and machine-learning methods in natural-product research
ReviewScopeStated limit
Mullowney et al., Nat Rev Drug Discov 2023;22:895–916Computational omics combined with machine learning for activity prediction and de novo design applied to natural productsStates the need for high-quality datasets to train deep-learning algorithms and for appropriate strategies to validate algorithms
Atanasov et al., Nat Rev Drug Discov 2021;20:200–216Analytical tools, genome mining and engineering, and microbial culturing advancesDescribes technical barriers to screening, isolation, characterization and optimization that reduced industry interest from the 1990s
Newman and Cragg, J Nat Prod 2020;83:770–803Sources of approved drugs from January 1981 to September 2019, with a category for FDA-recognized botanical defined mixturesA classification review of approvals, not a prediction of future output

DOIs: 10.1038/s41573-023-00774-7; 10.1038/s41573-020-00114-z; 10.1021/acs.jnatprod.9b01285. Read October 28, 2026.

Related: what a botanical model would need to be trained on · the paired data a laboratory would have to generate · computational methods in use

Solvents and delivery

Two frontiers covered elsewhere

Two active areas are treated in full on their own pages, so they are only placed in time here. Natural deep eutectic solvents were described in 2013 as a class of more than 100 mixtures of plant primary metabolites; the extraction page sets out what they can and cannot yet do, including the regulatory position. Delivery systems are judged by measured pharmacokinetics, not by particle size.

Read instead: deep eutectic solvents, solvent limits and recovery · delivery systems and what a bioavailability study must show · absorption, distribution, metabolism and excretion

Registered trials

Compounds in late-phase trials

A compound is listed here only if a phase 3 record exists on ClinicalTrials.gov. The table reports registry fields: phase, status, sponsor, enrollment and dates. It reports no results and no efficacy, and registration is not approval.

Phase 3 ClinicalTrials.gov records for plant- and fungus-derived investigational drugs
RecordIntervention as describedPhase and statusSponsor (class)EnrollmentStart
NCT04993729T89 capsule, described in the record as "a botanical drug containing 75mg active substance which is the water extract of Danshen and Sanqi"Phase 3; completedTasly Pharmaceuticals, Inc. (industry)853 (actual)July 21, 2021
NCT07426120Botanical total coumarin cream, applied topically, against a vehicle creamPhase 3; recruitingPsoriasis Research Institute of Guangzhou (industry)300 (estimated)February 1, 2026
NCT05624268COMP360 psilocybin, single administrationPhase 3; completedCOMPASS Pathways (industry)258 (actual)January 24, 2023
NCT05711940COMP360 psilocybin, two administrationsPhase 3; active, not recruitingCOMPASS Pathways (industry)572 (actual)February 14, 2023
NCT06308653Psilocybin 25 mg or 5 mg, stated in the record to be synthetically manufacturedPhase 3; active, not recruitingUsona Institute (other)238 (actual)March 13, 2024
NCT07226232Psilocybin, two doses comparedPhase 3; recruitingVA Office of Research and Development (federal)240 (estimated)August 3, 2026

ClinicalTrials.gov API v2 records, retrieved October 28, 2026. Every record above is flagged in the registry as an FDA-regulated drug study. "Results posted" was false for all six on that date.

Regulatory status, stated precisely. Psilocybin is listed as a Schedule I hallucinogenic substance at 21 CFR 1308.11(d)(29), drug code 7437. A query of Drugs@FDA through the openFDA drug application endpoint on October 28, 2026 returned no approved application with psilocybin as an active ingredient. FDA's guidance Psychedelic Drugs: Considerations for Clinical Investigations (docket FDA-2023-D-1987) is final and dated July 2026; it finalizes a draft issued in 2023. A phase 3 registration means a trial exists, not that a product is approved or that any benefit is established.

Notes and sources

Botanical drug development has its own FDA guidance, Botanical Drug Development (final, December 2016, docket FDA-2000-D-0103), which covers investigational new drug applications and new drug applications for botanical products. The two botanical records above are both multi-component plant preparations, which is the case that guidance addresses. Sponsor class ("industry", "other", "federal") is the registry's own field.

Explore

Filter the advances

The same items, arranged by kind against a year axis. Choose a kind to bring its markers forward; the rest stay in place, dimmed, so the timing can still be compared.

Nineteen items by kind and year, filteredPapers, agency record and registry
Show one kind

All 19 items shown.

Map of the advances on this page: one row for each kind of advance and one marker for each item, placed on a year axis from 2004 to 2026. Radio buttons under the figure show one kind at a time.Each advance by kind and year (2004 shown for the plant-cell-fermentation award)Pathways rebuilt in a hostArtemisinic acid, yeast (2013). Paddon et al., Nature 2013: 25 g/L artemisinic acid; chemical conversion to artemisininArtemisinic acid, yeastCannabinoids, yeast (2019). Luo et al., Nature 2019: complete biosynthesis from galactoseCannabinoids, yeastVindoline, catharanthine, yeast (2022). Zhang et al., Nature 2022: 30 enzymatic steps, 56 genetic editsVindoline,catharanthine, yeastQS-21, yeast (2024). Liu et al., Nature 2024: 38 heterologous enzymes from six organismsQS-21, yeastBaccatin III, Nicotiana (2025). McClune et al., Nature 2025: 17-gene de novo route in N. benthamianaBaccatin III, NicotianaAnalytics and open resourcesGNPS (2016). Wang et al., Nat Biotechnol 2016: open MS/MS knowledge base and molecular networkingGNPSSIRIUS 4 (2019). Dührkop et al., Nat Methods 2019: over 70% identification rates on test datasetsSIRIUS 4CANOPUS (2021). Dührkop et al., Nat Biotechnol 2021: 2,497 compound classes from fragmentation spectraCANOPUSantiSMASH 7 (2023). Blin et al., Nucleic Acids Res 2023: 81 cluster typesantiSMASH 7MIBiG 4.0 (2024). Zdouc et al., Nucleic Acids Res 2024: 3,059 curated entriesMIBiG 4.0antiSMASH 8 (2025). Blin et al., Nucleic Acids Res 2025: 101 cluster typesantiSMASH 8Machine learning (reviews)Natural-product review (2021). Atanasov et al., Nat Rev Drug Discov 2021: genome mining, analytics, culturingNatural-productreviewAI review (2023). Mullowney et al., Nat Rev Drug Discov 2023: data quality and validation as the limitsAI reviewSolvents and deliveryPlant cell fermentation (2004). EPA Presidential Green Chemistry Challenge 2004 award: paclitaxel by Taxus cell culturePlant cell fermentationDeep eutectic mixtures (2013). Dai et al., Anal Chim Acta 2013: more than 100 natural deep eutectic mixturesDeep eutecticmixturesRegistered human trialsT89 (Danshen, Sanqi) (2021). NCT04993729: phase 3, 853 participants, completed 2023T89 (Danshen, Sanqi)Psilocybin, TRD (2023). NCT05624268 and NCT05711940: phase 3, 258 and 572 participantsPsilocybin, TRDPsilocybin, MDD (2024). NCT06308653: phase 3, 238 participants, active, not recruitingPsilocybin, MDDTotal coumarin cream (2026). NCT07426120: phase 3, 300 planned, recruitingTotal coumarin cream200420062008201020122014201620182020202220242026Advances on this page listed by kind, each with its year. Radio buttons under the figure show one kind at a time.Each advance by kind and yearPathways rebuilt in a hostPaddon et al., Nature 2013: 25 g/L artemisinic acid; chemical conversion to artemisinin2013 Artemisinic acid, yeastLuo et al., Nature 2019: complete biosynthesis from galactose2019 Cannabinoids, yeastZhang et al., Nature 2022: 30 enzymatic steps, 56 genetic edits2022 Vindoline, catharanthine, yeastLiu et al., Nature 2024: 38 heterologous enzymes from six organisms2024 QS-21, yeastMcClune et al., Nature 2025: 17-gene de novo route in N. benthamiana2025 Baccatin III, NicotianaAnalytics and open resourcesWang et al., Nat Biotechnol 2016: open MS/MS knowledge base and molecular networking2016 GNPSDührkop et al., Nat Methods 2019: over 70% identification rates on test datasets2019 SIRIUS 4Dührkop et al., Nat Biotechnol 2021: 2,497 compound classes from fragmentation spectra2021 CANOPUSBlin et al., Nucleic Acids Res 2023: 81 cluster types2023 antiSMASH 7Zdouc et al., Nucleic Acids Res 2024: 3,059 curated entries2024 MIBiG 4.0Blin et al., Nucleic Acids Res 2025: 101 cluster types2025 antiSMASH 8Machine learning (reviews)Atanasov et al., Nat Rev Drug Discov 2021: genome mining, analytics, culturing2021 Natural-product reviewMullowney et al., Nat Rev Drug Discov 2023: data quality and validation as the limits2023 AI reviewSolvents and deliveryEPA Presidential Green Chemistry Challenge 2004 award: paclitaxel by Taxus cell culture2004 Plant cell fermentationDai et al., Anal Chim Acta 2013: more than 100 natural deep eutectic mixtures2013 Deep eutectic mixturesRegistered human trialsNCT04993729: phase 3, 853 participants, completed 20232021 T89 (Danshen, Sanqi)NCT05624268 and NCT05711940: phase 3, 258 and 572 participants2023 Psilocybin, TRDNCT06308653: phase 3, 238 participants, active, not recruiting2024 Psilocybin, MDDNCT07426120: phase 3, 300 planned, recruiting2026 Total coumarin cream
Without JavaScript, all items are shown; the tables above carry the same content.Items and dates as in the tables on this page: papers by year of publication, the EPA award by year of award (2004), trials by registered start date.
Proposal

Where EUTECNIQ would work

Proposed EUTECNIQ would not rebuild pathways. It would work where these advances meet a product decision: untargeted analysis to characterize an extract, open cluster and spectral resources to read the literature against a lot, and paired laboratory records so that any model it later used could be tested. No strain engineering, no clinical sponsorship.

Related pages: Large Botanical Model · Data asset · From plant to prescription · Discovery and characterization · Clinical research

Health information notice

These statements have not been evaluated by the Food and Drug Administration. Nothing on this site is intended to diagnose, treat, cure or prevent any disease. The information is for general education only. It is not medical advice and does not replace advice, diagnosis or treatment from a qualified health professional, or any medication a clinician has prescribed.

Do not start, stop or change any medicine, supplement or herbal product because of something you read here. Talk to your doctor or pharmacist first, especially if you are pregnant or breastfeeding, have a medical condition, take any medicines, are preparing for surgery, or are caring for a child. Research findings, traditional uses and safety data are reported as their sources state them; they are not recommendations or claims about any product. If you think you may have a medical emergency, call your doctor or 911 at once.

EUTECNIQ Sciences sells no supplements or health products today and receives nothing from any product or ingredient mentioned on this site; any commercial interest it later has in an ingredient will be stated on that ingredient’s page.

Ready to start a development project?

Tell us about an ingredient you want to specify, verify or license. Questions? Email [email protected]